BriaCell Therapeutics Corp.
Suite 300 – 235 West 15th Street
West Vancouver, BC V7T 2X1
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Division of Corporation Finance
Attention: Irene Paik, Joseph McCann, Franklin Wyman and Lisa Vanjoske
May 27, 2020 |
Re: | BriaCell Therapeutics Corp. |
Amendment No. 8 to Registration Statement on Form F-1 Filed May 27, 2020 | |
File No. 333-234292 |
Ladies and Gentlemen:
BriaCell Therapeutics Corp. (the “Company”) is hereby filing Amendment No. 8 to its Registration Statement on Form F-1/A (“Amendment No. 8”). Amendment No. 8 has been revised to reflect i) the change to a reasonable efforts offering on the OTCQB from an underwritten offering on Nasdaq, ii) maximum gross proceeds of up to $4 million from up to $15.755 million and iii) describe the new terms of the investor warrant.
Please do not hesitate to contact our counsel at (212) 930-9700 with any questions or comments regarding this correspondence.
Sincerely, | |
/s/ William V. Williams | |
William V. Williams |
cc: (via email)
Jamieson Bondarenko
Gadi Levin
Gregory Sichenzia, Esq.
Avital Perlman, Esq.
Aaron Sonshine
Virgil Z. Hlus